Darren Moore, PhD

Darren J. Moore received his PhD in molecular neuroscience from the University of Cambridge in 2001 in the laboratory of Dr. Piers Emson, and conducted postdoctoral research with Dr. Ted Dawson in the Institute for Cell Engineering and Udall Parkinson’s Disease Center of Excellence at the Johns Hopkins University School of Medicine. He joined the Department of Neurology faculty at Johns Hopkins in 2006 as assistant professor, before moving to the Brain Mind Institute of the Swiss Federal Institute of Technology (EPFL) in 2008.

In 2014, Dr. Moore returned to the United States and was appointed as associate professor in the newly created Center for Neurodegenerative Science at the Van Andel Institute in Michigan and was promoted to full professor in 2017. His research focuses on understanding the cell biology and pathophysiological mechanisms underlying familial and risk genes for PD, including LRRK2, VPS35, alpha-synuclein, tau and ATP13A2, and their contributions to the endolysosomal pathway.

Van Andel Institute | Grand Rapids, USA
CO-INVESTIGATOR

Darren Moore, PhD

Van Andel Institute

Darren J. Moore received his PhD in molecular neuroscience from the University of Cambridge in 2001 in the laboratory of Dr. Piers Emson, and conducted postdoctoral research with Dr. Ted Dawson in the Institute for Cell Engineering and Udall Parkinson’s Disease Center of Excellence at the Johns Hopkins University School of Medicine. He joined the Department of Neurology faculty at Johns Hopkins in 2006 as assistant professor, before moving to the Brain Mind Institute of the Swiss Federal Institute of Technology (EPFL) in 2008.

In 2014, Dr. Moore returned to the United States and was appointed as associate professor in the newly created Center for Neurodegenerative Science at the Van Andel Institute in Michigan and was promoted to full professor in 2017. His research focuses on understanding the cell biology and pathophysiological mechanisms underlying familial and risk genes for PD, including LRRK2, VPS35, alpha-synuclein, tau and ATP13A2, and their contributions to the endolysosomal pathway.